Introduction
Cilostazol is a medication used under the brand name Pletal for the treatment of intermittent claudication and secondary prevention in certain patients․ Its mechanism of action involves phosphodiesterase (PDE) III inhibition to increase cAMP levels․
Overview of Cilostazol (Pletal)
Cilostazol‚ marketed as Pletal‚ is primarily used for the treatment of intermittent claudication and secondary prevention in certain patients․ It functions by inhibiting phosphodiesterase (PDE) III‚ leading to increased cAMP levels․ Commonly available in 50 mg triangular and 100 mg round tablets for oral administration‚ Cilostazol improves walking distance in peripheral vascular disease by promoting vasodilation and antiplatelet activity․
Recommended Dosage
Therapeutic dosing of Cilostazol typically involves a regimen of 100 mg orally twice daily․ The medication is usually taken without food‚ approximately 30 minutes before or 2 hours after meals․ Adjustments in dosage may be necessary based on individual patient characteristics․
Therapeutic Dosing of Cilostazol
Cilostazol is typically recommended to be taken as a 100 mg oral dose twice daily․ The medication is advised to be consumed without food‚ either 30 minutes before or 2 hours after meals․ Dosing adjustments might be required in certain cases based on individual patient response and medical considerations․
Dosage Forms
Cilostazol (Pletal) tablets are available in two strengths⁚ 50 mg triangular and 100 mg round tablets for oral administration․ The tablets contain inactive ingredients in addition to the active compound․
Available Tablet Strengths
Cilostazol (Pletal) tablets come in two strengths⁚ 50 mg triangular and 100 mg round tablets for oral administration․ Each tablet contains inactive ingredients along with the active compound․ These different strengths accommodate individualized dosage requirements for patients․
Administration Guidelines
Proper way to take Cilostazol involves oral administration without food‚ usually 30 minutes before or 2 hours after meals․ The dosing regimen typically consists of 100 mg taken twice daily‚ with adjustments based on individual response․
Proper Way to Take Cilostazol
Patients are advised to take Cilostazol orally without food‚ typically twice daily at least 30 minutes before or 2 hours after breakfast and dinner․ The dosage regimen usually consists of 100 mg per dose‚ with adjustments based on individual needs and response․
Dosage Adjustment
Considerations for dose modification may be applied to cilostazol based on individual responses and patient-specific factors․ The typical dosage regimen consists of 100 mg taken twice daily‚ with potential adjustments as needed․
Considerations for Dose Modification
When it comes to dose adjustments for Cilostazol‚ individual responses and specific patient factors play a crucial role․ The standard dosing typically involves 100 mg taken twice daily‚ with the potential for modifications as warranted by the patient’s condition․
Drug Interactions
The U․S․ Food and Drug Administration identifies potential interactions affecting Cilostazol’s dosage with drugs like macrolide antibiotics‚ diltiazem‚ and others that impact CYP3A4 and CYP2C19 activity․
Potential Interactions Affecting Dosage
Interactions affecting the dosage of Cilostazol involve drugs such as macrolide antibiotics‚ diltiazem‚ and others known to impact CYP3A4 and CYP2C19 enzyme activity․ These interactions can alter the clearance and efficacy of Cilostazol‚ necessitating dose adjustments or careful monitoring․
Side Effects
Common adverse reactions to Cilostazol may include diarrhea‚ headache‚ or fast heartbeats․ It is essential for patients to be aware of these potential side effects and consult a healthcare provider for further guidance․
Common Adverse Reactions to Cilostazol
Common adverse reactions to Cilostazol may include diarrhea‚ headache‚ or fast heartbeats․ It is vital for patients to be aware of these potential side effects and consult healthcare professionals for further guidance if needed․
Patient Information
Patients taking Cilostazol should be aware of potential side effects like diarrhea‚ headache‚ and fast heartbeats․ It is crucial to consult healthcare providers promptly for guidance and monitoring․
Important Instructions for Patients Taking Cilostazol
Patients taking Cilostazol should be cautious of potential side effects such as diarrhea‚ headache‚ and fast heartbeats․ If experiencing any severe or prolonged adverse effects‚ it is advised to seek immediate medical advice․
10 responses to “Dosage and Administration of Pletal (Cilostazol)”
The article on Cilostazol presents a thorough overview of the medication, focusing on its application in intermittent claudication and secondary prevention. The explanation of how PDE III inhibition leads to increased cAMP levels is elucidated effectively.
The overview of Cilostazol (Pletal) in the article effectively summarizes its primary use for intermittent claudication and secondary prevention. The role of phosphodiesterase (PDE) III inhibition in increasing cAMP levels is a key point in understanding its mechanism of action.
The article offers a detailed insight into Cilostazol (Pletal) and its therapeutic uses, particularly in intermittent claudication and secondary prevention. The mechanism of action involving phosphodiesterase (PDE) III inhibition is elucidated clearly for the readers.
The overview of Cilostazol (Pletal) provided in the article is informative and well-structured, focusing on its role in managing intermittent claudication and secondary prevention. The explanation of PDE III inhibition and cAMP level increase enhances comprehension.
The overview of Cilostazol (Pletal) in the article is comprehensive, providing valuable information on its use for intermittent claudication and secondary prevention. The discussion on phosphodiesterase (PDE) III inhibition enhances the understanding of its mode of action.
The article effectively communicates the essential details about Cilostazol (Pletal) and its pharmacological mechanism, emphasizing its benefits in treating intermittent claudication and secondary prevention. The role of PDE III inhibition is well-explained.
The article provides a concise introduction to the medication Cilostazol, highlighting its use in treating intermittent claudication and secondary prevention in specific patient populations. The mechanism of action involving phosphodiesterase (PDE) III inhibition is clearly explained.
The article presents a clear and informative overview of Cilostazol (Pletal) and its pharmacological action. The emphasis on PDE III inhibition and its impact on cAMP levels helps in elucidating how the medication works in the body.
The article effectively outlines the key information about Cilostazol (Pletal), shedding light on its application in intermittent claudication and secondary prevention. The mechanism of action through PDE III inhibition is a crucial aspect highlighted in the text.
The discussion on Cilostazol